CDAN1

Summary

Gene Symbol: CDAN1
Description: codanin 1
Alias: CDA1, CDAI, CDAN1A, DLT, PRO1295, codanin-1, congenital dyserythropoietic anemia, type I, discs lost homolog
Species: human

Top Publications

  1. ncbi A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma
    A Callari
    Service of Chemotherapy, Oncological Hospital M. Ascoli, Palermo, Italy
    Acta Oncol 33:925-9. 1994
  2. ncbi Remote glucosyltransferase-microparticle vaccine delivery induces protective immunity in the oral cavity
    D J Smith
    Department of Immunology, The Forsyth Institute, Boston, MA 02115, USA
    Oral Microbiol Immunol 18:240-8. 2003
  3. pmc Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer
    A Ardizzoni
    Division of Medical Oncology I, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
    Br J Cancer 74:1141-7. 1996
  4. pmc The dlt operon of Bacillus cereus is required for resistance to cationic antimicrobial peptides and for virulence in insects
    Z Abi Khattar
    INRA, UMR 1133, Laboratoire EMIP, Place Eugene Bataillon, F 34095 Montpellier, France
    J Bacteriol 191:7063-73. 2009
  5. ncbi Total parenteral nutrition in treatment of patients with inflammatory bowel disease
    Kalina Grivceva Stardelova
    Gastroenterohepatology Clinic, Medical Faculty, Skopje, R Macedonia
    Prilozi 29:21-43. 2008
  6. ncbi Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group
    G Frasci
    Division of Medical Oncology A, National Tumor Institute, Naples, Italy
    Breast Cancer Res Treat 56:239-52. 1999
  7. ncbi Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma
    G C de Gast
    Division of Medical Oncology, Antoni van Leeuwenhoek Hospital Netherlands Cancer Institute, Amsterdam
    Clin Cancer Res 6:1267-72. 2000
  8. ncbi Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome
    Jon C Mirsalis
    Toxicology Laboratory, SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025 3493, USA
    Cancer Chemother Pharmacol 51:193-201. 2003
  9. ncbi Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer
    Antonius A Miller
    Comprehensive Cancer Center of Wake Forest University, Section on Hematology and Oncology, Medical Center Boulevard, Winston Salem, NC 27157, United States
    Lung Cancer 54:379-85. 2006
  10. doi Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study
    Pol Specenier
    Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
    Anticancer Drugs 21:306-12. 2010

Detail Information

Publications189 found, 100 shown here

  1. ncbi A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma
    A Callari
    Service of Chemotherapy, Oncological Hospital M. Ascoli, Palermo, Italy
    Acta Oncol 33:925-9. 1994
    ..of the study, groups of 3 patients received EDXR 20, 25, 30, 35, and 40 mg/m2/day until the dose limiting toxicity (DLT) was reached...
  2. ncbi Remote glucosyltransferase-microparticle vaccine delivery induces protective immunity in the oral cavity
    D J Smith
    Department of Immunology, The Forsyth Institute, Boston, MA 02115, USA
    Oral Microbiol Immunol 18:240-8. 2003
    ..and 21 with a) GTF-MP alone, b) GTF-MP with cholera toxin, c) GTF-MP with detoxified mutant Escherichia coli toxin (dLT), or d) sham immunized with PLGA and cholera toxin...
  3. pmc Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer
    A Ardizzoni
    Division of Medical Oncology I, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
    Br J Cancer 74:1141-7. 1996
    ..3) completed three or more cycles at the dose and schedule planned by the protocol and no 'dose-limiting toxicity' (DLT) was seen...
  4. pmc The dlt operon of Bacillus cereus is required for resistance to cationic antimicrobial peptides and for virulence in insects
    Z Abi Khattar
    INRA, UMR 1133, Laboratoire EMIP, Place Eugene Bataillon, F 34095 Montpellier, France
    J Bacteriol 191:7063-73. 2009
    The dlt operon encodes proteins that alanylate teichoic acids, the major components of cell walls of gram-positive bacteria...
  5. ncbi Total parenteral nutrition in treatment of patients with inflammatory bowel disease
    Kalina Grivceva Stardelova
    Gastroenterohepatology Clinic, Medical Faculty, Skopje, R Macedonia
    Prilozi 29:21-43. 2008
    ..the course of the study, the following parameters were examined: Body mass index (BMI), Disease Activity Index (CDAI/AI), laboratory parameters and the number of hospital days...
  6. ncbi Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group
    G Frasci
    Division of Medical Oncology A, National Tumor Institute, Naples, Italy
    Breast Cancer Res Treat 56:239-52. 1999
    ..Weekly administration could result in a substantial improvement in the therapeutic index of cisplatin and paclitaxel. This study was aimed at determining the MTDs of epirubicin and paclitaxel given weekly with a fixed dose of cisplatin...
  7. ncbi Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma
    G C de Gast
    Division of Medical Oncology, Antoni van Leeuwenhoek Hospital Netherlands Cancer Institute, Amsterdam
    Clin Cancer Res 6:1267-72. 2000
    The purpose of our study was to determine the maximally tolerated dose (MTD) and DLT of combined administration of granulocyte macrophage colony-stimulating factor (GM-CSF), low-dose interleukin 2 (IL-2) and IFN-alpha in patients with ..
  8. ncbi Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome
    Jon C Mirsalis
    Toxicology Laboratory, SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025 3493, USA
    Cancer Chemother Pharmacol 51:193-201. 2003
    ..studies in rats and dogs to determine the maximum tolerated dose (MTD) and identify dose-limiting toxicities (DLT) in each species in different regimens to establish a safe starting dose and potential target organs of DX-52-1 for ..
  9. ncbi Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer
    Antonius A Miller
    Comprehensive Cancer Center of Wake Forest University, Section on Hematology and Oncology, Medical Center Boulevard, Winston Salem, NC 27157, United States
    Lung Cancer 54:379-85. 2006
    ..Follow-up was weekly for CBC. Tumor response was assessed after 2 and 6 cycles. Dose limiting toxicity (DLT) was defined as any of the following in cycle 1: grade 3 or 4 non-hematologic toxicity other than nausea and ..
  10. doi Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study
    Pol Specenier
    Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
    Anticancer Drugs 21:306-12. 2010
    ..ifosfamide and cisplatin in patients with solid tumours and to define the safety, dose-limiting toxicity (DLT) and the recommended dose and administration schedule of docetaxel, ifosfamide and cisplatin for further phase II ..
  11. ncbi Phase I study of docetaxel and topotecan in patients with solid tumors
    K H Tkaczuk
    University of Maryland Greenebaum Cancer Center, 22 South Greene St, Baltimore, MD 21201, USA
    Cancer Chemother Pharmacol 46:442-8. 2000
    ..This phase I trial was conducted to determine the overall and dose-limiting toxicities (DLT), the maximum tolerated dose (MTD) and the pharmacokinetics of the combination of DOC and TOPO in patients with ..
  12. ncbi A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers
    P Bhargava
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Clin Cancer Res 7:3912-9. 2001
    ..in patients with advanced cancers to: (a) determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and pharmacokinetics of squalamine lactate when given as a 120-h continuous i.v...
  13. doi Choosing a lung isolation device for thoracic surgery: a randomized trial of three bronchial blockers versus double-lumen tubes
    Manu Narayanaswamy
    Gosford Hospital, Gosford, New South Wales 2250, Australia
    Anesth Analg 108:1097-101. 2009
    ..In this study, we compared the clinical performance of three bronchial blockers (BBs) available in North America with left-sided double-lumen tubes (DLTs) for lung isolation in patients undergoing left-sided thoracic surgery...
  14. ncbi Incorporation of D-alanine into lipoteichoic acid and wall teichoic acid in Bacillus subtilis. Identification of genes and regulation
    M Perego
    Dipartimento Farmaceutico, Facolta di Farmacia, Universita degli Studi di Parma, Italy
    J Biol Chem 270:15598-606. 1995
    The Bacillus subtilis dlt operon (D-alanyl-lipoteichoic acid) is responsible for D-alanine esterification of both lipoteichoic acid (LTA) and wall teichoic acid (WTA). The dlt operon contains five genes, dltA-dltE...
  15. ncbi Anti-interleukin-12 antibody for active Crohn's disease
    Peter J Mannon
    Mucosal Immunity Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 351:2069-79. 2004
    ..Crohn's disease is associated with excess cytokine activity mediated by type 1 helper T (Th1) cells. Interleukin-12 is a key cytokine that initiates Th1-mediated inflammatory responses...
  16. pmc A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study
    D Sebag-Montefiore
    Cookridge Hospital, Hospital Lane, Cookridge, West Yorkshire LS16 6QB, UK
    Br J Cancer 93:993-8. 2005
    ..The MTD was determined as the dose causing more than a third of patients to have a dose-limiting toxicity (DLT). Once the MTD was reached, a further 14 patients were treated at the dose level below the MTD...
  17. pmc A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study
    R Glynne-Jones
    Mount Vernon Cancer Centre, Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK
    Br J Cancer 96:551-8. 2007
    ..The MTD was determined as the dose causing more than a third of patients to have a dose-limiting toxicity (DLT) defined as specific grade 3 or 4 toxicities...
  18. ncbi Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial
    W Scheithauer
    Department of Internal Medicine I, Division of Oncology, University Medical School, Vienna, Austria
    Cancer 91:1264-71. 2001
    ..The aim of this disease oriented Phase I-II study was to determine the maximum tolerated dose (MTD), the dose-limiting toxicities (DLT), and the objective response rate of this combination in patients with advanced colorectal carcinoma.
  19. ncbi [Anesthesia in single and bilateral sequential lung transplantation. Lung Transplantation Group]
    G Della Rocca
    Istituto di Anestesia e Rianimazione, Universita degli Studi di Roma La Sapienza
    Minerva Anestesiol 66:183-93. 2000
    ..Anesthesia for lung transplantation: intraoperative complications and long term results...
  20. ncbi Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors
    D Mavroudis
    Department of Medical Oncology, University General Hospital of Heraklion, Greece
    Oncology 62:216-22. 2002
    ..We conducted a phase I study to determine the maximum tolerated doses (MTD) and the dose limiting toxicities (DLT) of the combination administered every 2 weeks in patients with advanced solid tumors.
  21. ncbi Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial
    Thomas Kuhnt
    Department of Radiotherapy, Martin Luther University, Halle, Germany
    Strahlenther Onkol 179:673-81. 2003
    ..combination protocol with cisplatin and escalated paclitaxel in combination with accelerated hyperfractionated radiotherapy to assess the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), overall toxicity, and response rate.
  22. ncbi Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study
    G L Phillips
    Blood and Marrow Transplant Program, University of Kentucky, Lexington, USA
    Biol Blood Marrow Transplant 10:473-83. 2004
    This study was conducted to define a new maximum tolerated dose and the dose-limiting toxicity (DLT) of melphalan and autologous hematopoietic stem cell transplantation (AHSCT) when used with the cytoprotective agent amifostine...
  23. ncbi Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas
    O S Nielsen
    Aarhus University Hospital, Department of Oncology, Norrebrogade 44, DK 8000 Aarhus C, Denmark
    Eur J Cancer 42:2303-9. 2006
    ..5 g; L4 and L5: X = 3 g. Cohorts of 3 patients were entered at each level unless a dose-limiting toxicity (DLT) occurred. In case of DLT in 1 of 3 patients a new cohort was added...
  24. pmc Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer
    Nicholas W Choong
    Section of Hematology Oncology, University of Chicago Medical Center, Chicago, IL 60615, USA
    J Thorac Oncol 3:59-67. 2008
    ....
  25. doi Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study
    Evangelos Briasoulis
    Department of Medical Oncology, Ioannina University Hospital, Greece
    Anticancer Drugs 21:785-9. 2010
    ..Patients with advanced cancer were eligible for this trial. Dose-limiting toxicity (DLT) was considered to be any grade greater than or equal to 3 (G> or =3) nonhematological toxicity except nausea/..
  26. ncbi Positioning of a double-lumen endobronchial tube without the aid of any instruments: an implication for emergency management
    J H Bahk
    Department of Anesthesiology and Clinical Research Institute, Seoul National University Hospital, Korea
    J Trauma 49:899-902. 2000
    ..If bleeding continues but the side of origin is uncertain, use of a double-lumen tube (DLT) is reasonable...
  27. ncbi MR of the small bowel with a biphasic oral contrast agent (polyethylene glycol): technical aspects and findings in patients affected by Crohn's disease
    Andrea Laghi
    Dipartimento di Scienze Radiologiche, Universita degli Studi di Roma La Sapienza, Rome, Italy
    Radiol Med 106:18-27. 2003
    ..To report our experience using MR of the small bowel with polyethylene glycol (PEG) solution as an oral contrast agent in a population of adults and children with known Crohn's disease...
  28. ncbi [Therapeutic effects of combined enteral nutrition with Tripterygium Wilfordii poly-glycoside in remission induction of active adult Crohn's disease]
    Jian feng Gong
    Research Institute of General Surgery, Nanjing General Hospital of Nanjing Military Command, Nanjing 210002, China
    Zhonghua Wai Ke Za Zhi 47:1213-7. 2009
    ..To investigate the potential role of enteral nutrition (EN) combined with Tripterygium Wilfordii Poly-glycoside (TWP) for remission induction of active adult Crohn's disease (CD)...
  29. ncbi Cloning, expression, and purification of cytidine deaminase from Arabidopsis thaliana
    S Vincenzetti
    Dipartimento di Scienze Morfologiche e Biochimiche Comparate, Universita di Camerino, Camerino MC, Italy
    Protein Expr Purif 15:8-15. 1999
    The complementary DNA (cDNA) coding for Arabidopsis thaliana cytidine deaminase 1 (AT-CDA1) was obtained from the amplified A. thaliana cDNA expression library, provided by R. W. Davis (Stanford University, CA)...
  30. doi Tolerance in DLA-haploidentical canine littermates following CD6-depleted marrow transplantation and donor lymphocyte transfusion
    Julia Zorn
    Helmholtz Zentrum Munchen, National Research Center for Environmental Health, Institute of Molecular Immunology, Clinical Cooperation Group Hematopoietic Cell Transplantation, Munich, Germany
    Exp Hematol 37:998-1006. 2009
    Donor lymphocyte transfusions (DLT) are effective in the treatment of leukemia after allogeneic stem cell transplantation. Graft-vs-host-disease (GVHD) is the major risk factor of DLT...
  31. pmc Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics
    D R Newell
    Medical School, University of Newcastle, UK
    Br J Cancer 81:760-8. 1999
    ..for 24 drugs, and in patients the maximum administered dose (MAD) was associated with dose-limiting toxicity (DLT) in initial clinical trials with 20 compounds...
  32. ncbi Bronchial blocker compared to double-lumen tube for one-lung ventilation during thoracoscopy
    C Bauer
    Anesthesiology Department, H pital Civil, Strasbourg University Hospital, France
    Acta Anaesthesiol Scand 45:250-4. 2001
    ..This study compared the Broncho-Cath double-lumen endotracheal tube with the Wiruthan bronchial blocker to determine the advantages of one device over the other during anaesthesia with one-lung ventilation for thoracoscopy...
  33. ncbi A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients
    M A Villalona-Calero
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA
    Ann Oncol 12:605-14. 2001
    ..The study also sought to recommend doses for subsequent disease-specific studies, identify clinically significant pharmacokinetic interactions, and detect preliminary antitumor activity...
  34. doi Prophylactic dexamethasone decreases the incidence of sore throat and hoarseness after tracheal extubation with a double-lumen endobronchial tube
    Sang Hyun Park
    Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, 300 Gumi dong, Seongnam City, Kyeonggi Do, 463 802, Korea
    Anesth Analg 107:1814-8. 2008
    ..are common complications after tracheal intubation, particularly after using a double-lumen endobronchial tube (DLT)...
  35. ncbi Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG)
    F Caponigro
    Medical Oncology A, National Tumor Institute G Pascale, Napoli, Italy
    Ann Oncol 11:575-80. 2000
    ..Preclinical data support the combination of CDDP and raltitrexed. The aim of the present study was to evaluate the combination of cisplatin, raltitrexed. LFA and 5-FU in a phase I-II study...
  36. ncbi Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I-II study
    Vittorio Gebbia
    Department of Experimental Oncology, University of Palermo, Italy
    Anticancer Drugs 14:359-64. 2003
    ..A phase I study was carried out to evaluate the dose-limiting toxicity (DLT) and the maximally tolerated dose (MTD) of PXT and EPI in combination with a fixed dose of cisplatin every 4 weeks...
  37. ncbi A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens
    Christos Kosmas
    Second Division of Medical Oncology, Department of Medicine, Metaxa Cancer Hospital, Piraues, 21 Apolloniou Street, 16341, Athens, Greece
    Cancer Chemother Pharmacol 59:51-9. 2007
    ..In the present phase I-II study, we evaluated the feasibility and efficacy of bi-weekly gemcitabine (GEM) + irinotecan (CPT-11) in patients with relapsed NSCLC...
  38. ncbi [Weekly paclitaxel with concurrent intensity-modulated radiotherapy for nasopharyngeal carcinoma: outcomes of a tolerance trial]
    Chun Yan Chen
    State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P R China
    Ai Zheng 26:398-402. 2007
    ..This study was to define the maximal tolerant dose (MTD) of paclitaxel in weekly paclitaxel with concurrent intensity-modulated radiotherapy (IMRT) for local-regionally advanced NPC...
  39. doi Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI
    Alain M Schoepfer
    Farncombe Family Institute of Digestive Health Research, McMaster University, Hamilton, Ontario, Canada
    Am J Gastroenterol 105:162-9. 2010
    ..The aim of this study was to evaluate the correlation between the SES-CD and fecal calprotectin, C-reactive protein (CRP), blood leukocytes, and the Crohn's disease activity index (CDAI).
  40. ncbi Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group
    K Ewe
    I Medizinische Klinik und Poliklinik, Johannes Gutenberg Universitat Mainz, Germany
    Eur J Gastroenterol Hepatol 11:277-82. 1999
    ..Endoscopic recurrence of Crohn's disease frequently occurs within weeks after 'curative' operation. Treatment with 3 x 1 mg oral pH-modified release budesonide was tried to prevent postoperative recurrence...
  41. ncbi Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group
    P Comella
    Division of Medical Oncology A, National Tumour Institute, Naples, Italy
    Oncology 60:127-33. 2001
    ....
  42. ncbi Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease
    B E Sands
    Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston, 02114, USA
    Aliment Pharmacol Ther 16:399-406. 2002
    ..Interleukin-11 is a mesenchymally derived cytokine with pleiotropic activities. A pilot study suggested therapeutic benefit of recombinant human interleukin-11 (rhIL-11) in patients with Crohn's disease...
  43. ncbi Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma
    David N Korones
    James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Cancer 97:1963-8. 2003
    ..Temozolomide may prove more effective in combination with other agents. Therefore, combination oral chemotherapy for these patients is a particularly attractive approach...
  44. ncbi Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group
    P Schoffski
    Department of Haematology and Oncology, Hannover Medical School, Hannover, Germany
    Ann Oncol 15:1816-24. 2004
    ..The current study was performed to determine the safety profile, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of the intravenous (i.v.) administration of aviscumine in cancer patients...
  45. ncbi Azathioprine as a postoperative prophylaxis reduces symptoms in aggressive Crohn's disease
    Pär Myrelid
    Department of Surgery, Unit of Colorectal Surgery, Linkoping University Hospital, Sweden
    Scand J Gastroenterol 41:1190-5. 2006
    ..This study comprises a subset of CD patients considered to have an aggressive disease course and chosen for treatment with Aza postoperatively...
  46. ncbi Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease
    Siew C Ng
    St Mark s Hospital, Harrow, UK
    Inflamm Bowel Dis 13:129-34. 2007
    ..This study aimed to evaluate the efficacy of oral tacrolimus in patients with inflammatory bowel disease (IBD) refractory to conventional therapy, including azathioprine, 6-mercaptopurine, and infliximab...
  47. ncbi Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 146:829-38. 2007
    ..No anti-TNF agent has been evaluated prospectively in patients with Crohn disease who had responded to another anti-TNF agent and then lost that response or were intolerant of the agent...
  48. pmc Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial
    T Ernst
    Onkologisches Zentrum, III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Theodor Kutzer Ufer 1 3, Mannheim 68167, Germany
    Br J Cancer 97:1475-9. 2007
    ..Cycles were repeated every 3 weeks. The primary aim was to determine the dose-limiting toxicities (DLT) during the first two treatment cycles and the maximum tolerated dose (MTD)...
  49. ncbi Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings
    Taina Sipponen
    Department of Medicine, Division of Gastroenterology, Helsinki University Central Hospital, Helsinki, Finland
    Inflamm Bowel Dis 14:40-6. 2008
    ..We evaluated the clinical significance of these neutrofil-derived proteins in assessment of Crohn's disease activity by comparing them with endoscopic disease activity and with Crohn's disease activity index (CDAI) and serum CRP.
  50. ncbi Inflation of the distal cuff by saline reduces the incidence of malposition of the bronchial tube during lung separation in patients receiving nitrous oxide
    Manzo Suzuki
    Department of Anesthesiology, Second Hospital Nippon Medical School, Kanagawa, Japan
    J Cardiothorac Vasc Anesth 21:838-42. 2007
    A common problem during lung separation is malposition of the double-lumen tube (DLT). It was hypothesized that inflation of the distal cuff with saline instead of air may reduce the incidence of malposition of the endobronchial tube.
  51. doi Dose escalation study of epirubicin and docetaxel in patients with advanced or recurrent breast cancer
    Ichiro Ichinose
    Department of Medicine, Fukuoka University School of Medicine, Fukuoka, Japan
    Chemotherapy 54:379-85. 2008
    ..To develop a combination of epirubicin (EPI) and docetaxel (DTX) in Japan, dose escalation and pharmacokinetic studies were performed in patients with advanced or recurrent breast cancer...
  52. doi Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)
    Brett A Leav
    MassBiologics, University of Massachusetts Medical School, Boston, MA, USA
    Vaccine 28:965-9. 2010
    ..Previous studies have demonstrated a correlation between Clostridium difficile anti-toxin A serum antibodies and protection against symptomatic disease and recurrence...
  53. doi Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease - A controlled clinical trial
    Simone Krebs
    Department of Nuclear Medicine, Faculty of Medicine, University of Freiburg, Germany
    Phytomedicine 17:305-9. 2010
    ..Minimum score of 200 on Crohn's Disease Activity Index (CDAI) was required at baseline for inclusion in each group...
  54. doi Age, dose, and time-dependency of plasma and tissue distribution of deltamethrin in immature rats
    Kyu Bong Kim
    Department of Pharmaceutical Engineering, Inje University, Gimhae, Gyongam 621 749, Korea
    Toxicol Sci 115:354-68. 2010
    The major objective of this project was to characterize the systemic disposition of the pyrethroid, deltamethrin (DLT), in immature rats, with emphasis on the age dependence of target organ (brain) dosimetry...
  55. pmc A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials
    Zhengjia Chen
    Rollins School of Public Health, Emory University, Atlanta, GA 30322, United States
    Contemp Clin Trials 31:473-82. 2010
    ..all current Phase I designs, toxicity response is treated coarsely as a binary indicator of dose limiting toxicity (DLT) and a lot of useful toxicity information is discarded...
  56. ncbi Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
    A M Senderowicz
    Developmental Therapeutics Program Clinical Trials Unit, Medicine Branch, Biostatistics and Data Management Section, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 16:2986-99. 1998
    ....
  57. ncbi Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer
    A A Yavuz
    Department of Radiation Oncology, Karadeniz Technical University, Faculty of Medicine, Trabzon, Turkey
    Int J Radiat Oncol Biol Phys 51:974-81. 2001
    To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of twice-weekly gemcitabine (TW-G) when administered in conjunction with fixed dose amifostine (A) during external radiotherapy (RT) in patients with advanced ..
  58. ncbi No evidence of de novo amyloidosis in recipients of domino liver transplantation: 12 to 40 (mean 24) month follow-up
    Paulo Lisboa Bittencourt
    Liver Unit, University of Sao Paulo School of Medicine, Brazil
    Amyloid 9:194-6. 2002
    Domino liver transplantation (DLT) has been performed for selected recipients at several centers, but de novo amyloidosis in recipients of livers from patients with familial amyloid polyneuropathy (FAP) remains a serious concern.
  59. pmc Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial
    R D Hofheinz
    Onkologisches Zentrum, III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Theodor Kutzer Ufer, D 68167 Mannheim, Germany
    Br J Cancer 91:834-8. 2004
    The aim of this study was to determine the dose-limiting toxicity (DLT) and establish the recommended dose for mitomycin C added every 3 weeks to the standard combination dose of capecitabine...
  60. ncbi Audit of double-lumen endobronchial intubation
    A H Seymour
    Department of Anaesthetics, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK
    Br J Anaesth 93:525-7. 2004
    Many technical variations are possible in the placing and management of a double-lumen tube (DLT). We surveyed our practice to relate these variations to the course of the anaesthetic.
  61. ncbi Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant Crohn's disease
    A Chrissafidou
    Marienhospital Bottrop, Abteilung fur Innere Medizin, Bottrop, Germany
    Z Gastroenterol 45:605-8. 2007
    ..Over time, however, approx. 20 % of patients develop steroid resistance. In these cases, alternative treatment methods are required. Short-term application of intravenous immunoglobulin (IVIg) may serve as an additional alternative...
  62. ncbi Properties of corynephage attachment site and molecular epidemiology of Corynebacterium ulcerans isolated from humans and animals in Japan
    Yukiji Seto
    Department of Bacterial Pathogenesis and Infection Control, National Institute of Infectious Diseases, Tokyo 208 0011, Japan
    Jpn J Infect Dis 61:116-22. 2008
    ..leo generated only phospholipase D (PLD), the other isolates produced both PLD and diphtheria-like toxin (DLT). Pulsed-field gel electrophoresis analysis showed that isolates from P. leo and humans were genetically homologous...
  63. ncbi Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies
    Julian R Molina
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    IDrugs 11:508-21. 2008
    ..In phase I clinical trials, the DLT for pralatrexate was mucositis, which could be abrogated with folic acid and vitamin B12 supplementation...
  64. doi A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma
    Monica Galli
    Div of Hematology, Ospedali Riuniti, Largo Barozzi, 1, 24128, Bergamo, Italy
    Ann Hematol 89:185-90. 2010
    ..Since two of them experienced a dose-limiting toxicity (DLT) during the first cycle, the subsequent patients received 100 mg ITF2357 twice daily...
  65. doi The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical care
    Daniel Aletaha
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Rheum Dis Clin North Am 35:759-72, viii. 2009
    ..and simple indices, such as the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI)...
  66. doi A randomized clinical trial comparing advanced pneumatic truncal, chest, and arm treatment to arm treatment only in self-care of arm lymphedema
    Sheila H Ridner
    Vanderbilt University School of Nursing, 461 21st Avenue South, Godchaux Hall, Nashville, TN 37240, USA
    Breast Cancer Res Treat 131:147-58. 2012
    ..although not empirically tested, therapeutic intervention delivered during decongestive lymphatic therapy (DLT)...
  67. doi Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method
    Emily M Van Meter
    Division of Cancer Biostatistics, Markey Cancer Center, University of Kentucky, Lexington, USA
    Clin Trials 9:303-13. 2012
    ..continual reassessment method (CRM), dichotomize toxicity outcomes based on prespecified dose-limiting toxicity (DLT) criteria...
  68. doi A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors
    R Salazar
    Instituto Catalán de Oncología, L Hospitalet de Llobregat, Avda Gran Via 199 203, Barcelona, Spain
    Cancer Chemother Pharmacol 70:673-81. 2012
    To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and recommended phase II dose (RD) of elisidepsin.
  69. pmc Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis
    Veena K Ranganath
    University of California at Los Angeles, 1000 Veteran Avenue, Rehab Building 32 59, Los Angeles, CA 90095, USA
    Rheumatology (Oxford) 52:1809-17. 2013
    ..the impact of comorbidities on achieving remission by examining changes in the clinical disease activity index (CDAI) in RA patients in the community-based Consortium of Rheumatology Researchers of North America (CORRONA) registry.
  70. doi Lack association of body mass index with disease activity composites of rheumatoid arthritis in Korean population: cross-sectional observation
    Jung Yoon Choe
    Devision of Rheumatology, Department of Internal Medicine, Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine, 3056 6 Daemyung 4 dong, Namgu, Daegu, 705 718, South Korea
    Clin Rheumatol 33:485-92. 2014
    ..composites including the Disease Activity Score 28 (DAS28) and the Clinical/Simplified Disease Activity Index (CDAI/SDAI) were assessed...
  71. pmc Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors
    Catherine G Lam
    Departments of Oncology Biostatistics, St Jude Children s Research Hospital, Memphis Department of Pediatrics, University of Tennessee Health Sciences Center, Memphis, TN Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD Department of Pediatric Hematology Oncology, Penn State Hershey Children s Hospital, Hershey, PA
    J Pediatr Hematol Oncol 37:e13-8. 2015
    ..Dose-limiting toxicity (DLT) and MTD were assessed at 3 dose levels in a 21-day regimen: day 1, oxaliplatin 130 mg/m (consistent dose); days 1 ..
  72. pmc VirR-Mediated Resistance of Listeria monocytogenes against Food Antimicrobials and Cross-Protection Induced by Exposure to Organic Acid Salts
    Jihun Kang
    Department of Food Science, Cornell University, Ithaca, New York, USA
    Appl Environ Microbiol 81:4553-62. 2015
    ..An experiment with a β-glucuronidase (GUS) reporter fusion with the dlt promoter indicated that nisin does not specifically induce VirR-dependent upregulation of dltABCD...
  73. doi Current Status of Single-Agent Phase I Trials in Japan: Toward Globalization
    Hidenori Mizugaki
    All authors National Cancer Center Hospital, Tokyo, Japan
    J Clin Oncol 33:2051-61. 2015
    ..However, the key findings of phase I trials in Japan and the West, such as dose-limiting toxicity (DLT) profiles and MTD or MAD levels, have not been compared.
  74. doi The importance of the Crohn's disease activity index in surgery for small bowel Crohn's disease
    J S Lee
    Department of Surgery, St Vincent s Hospital, College of Medicine, The Catholic University of Korea, Suwon, Republic of Korea
    J Visc Surg 153:339-345. 2016
    ..the relationship between postoperative morbidity in these patients as measured by three different scoring tools: general surgical risk (POSSUM score), disease activity (CDAI), and nutritional screening (nutritional prognostic index).
  75. pmc Increased Enterococcus faecalis infection is associated with clinically active Crohn disease
    Youlian Zhou
    aDepartment of Gastroenterology, Guangzhou Digestive Disease Center, Guangzhou First People s Hospital, Guangzhou Medical University, Guangzhou bThe First People s Foshan Hospital, Chancheng District, Foshan, Guangdong cDepartment of Pediatrics, Guangzhou First People s Hospital, Guangzhou Medical University dGuangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, P R China
    Medicine (Baltimore) 95:e5019. 2016
    ..015), Crohn disease activity index (CDAI; R = 0.3118, P = 0.0108), and fecal calprotectin (P = 0.016)...
  76. ncbi A chimeric anti-TNFalpha monoclonal antibody (cA2) in vivo removes TNFalpha-producing cells in Crohn's disease
    J M Urra
    Service of Immunology, Complejo Hospitalario de Ciudad Real, Spain
    Hum Antibodies 10:91-4. 2001
    ..Initially the patient, with severe Crohn's disease (Crohn's disease activity index CDAI > 350), presented a higher number of peripheral blood TNFalpha-producing cells than healthy controls...
  77. ncbi Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer
    V Alonso
    Division of Medical Oncology, Miguel Servet Hospital, Zaragoza, Spain
    Eur J Cancer 37:2385-91. 2001
    The aim of this study was to determine the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of weekly Irinotecan (CPT-11) plus UFT, and to assess the antitumour activity of this combination as second-line chemotherapy in ..
  78. ncbi Staphylococcus aureus strains lacking D-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice
    L Vincent Collins
    Department of Rheumatology, University of Goteborg, Goteborg, Sweden
    J Infect Dis 186:214-9. 2002
    ..The dlt operon mediates d-alanine incorporation into teichoic acids in the staphylococcal cell envelope and is a ..
  79. ncbi Changes in acute phase proteins after anti-tumor necrosis factor antibody (infliximab) treatment in patients with Crohn's disease
    V Kupcova
    Department of Internal Medicine, Derer s Hospital, Medical Faculty of Comenius University, Bratislava, Slovak Republic
    Physiol Res 52:89-93. 2003
    ..Clinical activity (assessed by Crohn's disease activity index - CDAI), alpha-1-acid glycoprotein, haptoglobin, cholinesterase and prealbumin were assessed before and in months 1 and 5 ..
  80. ncbi Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer
    Tomasz M Beer
    Divisions of Hematology and Medical Oncology, Oregon Health Sciences University and Portland Veterans Affairs Medical Center, Portland, Oregon 97239, USA
    Clin Cancer Res 10:1306-11. 2004
    The purpose is to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of mitoxantrone and docetaxel administered weekly before prostatectomy in men with localized prostate cancer at high risk for recurrence.
  81. ncbi A Phase I trial of protracted oral fixed-dose temozolomide
    Suzanne F Jones
    The Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Cancer 104:1985-91. 2005
    The current Phase I trial was conducted to determine the dose-limiting toxicity (DLT), maximum tolerated dose, and recommended Phase II dose of oral fixed-dose temozolomide when administered for 5 of every 7 days on a continuous basis.
  82. ncbi Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days
    Yasuhide Yamada
    Medical Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Sci 96:721-8. 2005
    ..Twenty-one patients received between one and eight cycles of E7070. The dose-limiting toxicities (DLT) comprised leukopenia, neutropenia, thrombocytopenia, elevation of aspartate aminotransferase, colitis, and ileus...
  83. ncbi Thoracic radiation therapy and concomitant low-dose daily paclitaxel in non-small cell lung cancer: a phase I study
    Carlo Gobitti
    Radiation Oncology Department, Centro di Riferimento Oncologico, National Cancer Institute, 33081 Aviano, Italy
    Oncol Rep 14:1647-53. 2005
    ..Two out of 6 patients experienced acute dose limiting toxicity (DLT) at the 12 mg/m2/day PTX dose level...
  84. ncbi Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study
    George P Stathopoulos
    First Oncology Department Errikos Dunant Hospital, Athens, Greece
    Anticancer Res 26:1489-93. 2006
    ..Our objectives were to determine the adverse reactions, dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of lipoxal.
  85. ncbi Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses
    Kenji Tamura
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Cancer Chemother Pharmacol 60:285-93. 2007
    To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics of TZT-1027 (soblidotin), a dolastatin 10 analogue, in Japanese patients with advanced solid tumors when administered on days 1 and 8 in 3-..
  86. ncbi Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn's disease
    Peter R Gibson
    Monash University Department of Medicine and Department of Gastroenterology, Box Hill Hospital, Box Hill, Victoria, Australia
    J Gastroenterol Hepatol 22:1306-12. 2007
    ..This study aimed to correlate disease severity with health-related quality of life and with health-care resource use, to allow evaluation of the cost effectiveness of these treatments...
  87. doi A phase I study of docetaxel and bexarotene
    Jonathan D Wildi
    Department of Medicine, Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Chemotherapy 54:125-30. 2008
    We conducted a single-arm, dose-escalation, phase 1 clinical trial in order to define the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of bexarotene in combination with docetaxel.
  88. doi Domino liver transplantation using a graft from a donor with familial hypercholesterolemia: seven-yr follow-up
    Irinel Popescu
    Center of General Surgery and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania
    Clin Transplant 23:565-70. 2009
    ..Only preliminary results of this domino liver transplantation (DLT) were published in 2003, without a long-term analysis of the hypercholesterolemic effects in recipient...
  89. doi Comparison of three rheumatoid arthritis disease activity scores in clinical routine
    B Rintelen
    Second Department of Medicine, Centre for Rheumatology, Lower Austria, State Hospital Stockerau, Karl Landsteiner Institute for Clinical Rheumatology, Stockerau, Austria
    Scand J Rheumatol 38:336-41. 2009
    ..activity cut-off values for the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) are in congruence with the Disease Activity Score including a 28-joint count (DAS28) disease activity criteria in ..
  90. doi Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma
    Takashi Watanabe
    Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
    Cancer Sci 101:196-200. 2010
    ..Vorinostat was well tolerated up to 200 mg with only one of six patients developing a dose-limiting toxicity (DLT; Grade 3 anorexia/hypokalemia)...
  91. doi Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma
    Higinia R Cardenes
    Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis 46202, USA
    Clin Transl Oncol 12:218-25. 2010
    ..Hepatocellular carcinoma (HCC) is increasing in incidence and the majority of patients are not candidates for radical therapies. Therefore, interest in minimally invasive therapies in growing...
  92. pmc Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report
    Maryam Fouladi
    St Jude Children s Research Hospital, Memphis, TN, USA
    J Clin Oncol 28:3623-9. 2010
    The purpose of this study was to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of vorinostat administered as a single agent and in combination 13-cis retinoic acid (13cRA) in children ..
  93. doi Prognostic evaluation of early rheumatoid arthritis
    Licia Maria Henrique da Mota
    Rheumatology Department of the Hospital Universitário de Brasília da Universidade de Brasília, Brasilia
    Swiss Med Wkly 140:w13100. 2010
    ..based on 28 joints (DAS 28), the simplified disease activity index (SDAI) and the clinical disease activity index (CDAI)...
  94. pmc Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients
    A Abajo
    Laboratory of Pharmacogenomics, Division of Oncology, Center for Applied Medical Research CIMA, University of Navarra, Pamplona, Spain
    Br J Cancer 103:1529-35. 2010
    To determine the dose-limiting toxicity (DLT), maximum tolerated dose, recommended dose (RD) and preliminary evidence of activity of escalating doses of irinotecan (CPT-11) fixed-dose-rate infusional gemcitabine (FDR-GMB) and bevacizumab ..
  95. doi Evaluation of disease activity indices in Korean patients with rheumatoid arthritis
    So Yeon Park
    Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul 133 792, Republic of Korea
    Rheumatol Int 32:545-9. 2012
    ..28-C-reactive protein (CRP), the simplified disease activity index (SDAI), and the clinical disease activity index (CDAI) against the DAS28-erythrocyte sedimentation rate (ESR) and determine cut-off values for each tool in Korean ..
  96. doi Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial
    F Arias de la Vega
    Department of Radiation Oncology, Hospital de Navarra, Pamplona, Spain
    Ann Oncol 23:1005-9. 2012
    ..Phase I study aims to determine the maximum tolerated dose and dose-limiting toxicity (DLT) of adding erlotinib to chemoradiation therapy in patients with surgically resected locally advanced SCCHN.
  97. ncbi [The importance of bronchoscopic anatomy for anesthesiologists]
    Tulay Hosten
    Department of Anesthesiology and Reanimation, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
    Tuberk Toraks 59:416-26. 2011
    ..Optimal and misplacement images of double-lumen tubes (DLT) and bronchial blockers (BB) used for OLV in our clinic were obtained via fiber optic bronchoscopy...
  98. doi Genome-wide transcriptional profiling of the cell envelope stress response and the role of LisRK and CesRK in Listeria monocytogenes
    Pia Kiil Nielsen
    Department of Biochemistry and Molecular Biology, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark
    Microbiology 158:963-74. 2012
    ..of genes that were strongly induced by cefuroxime exposure have cell-envelope-related functions, including the dlt operon and the gene encoding penicillin-binding protein PBPD2...
  99. doi Comparison of different camera calibration approaches for underwater applications
    Amanda Piaia Silvatti
    University of Campinas, SP, Brazil
    J Biomech 45:1112-6. 2012
    ..three camera calibration approaches applied to underwater applications: (1) static control points with nonlinear DLT; (2) moving wand with nonlinear camera model and bundle adjustment; (3) moving plate with nonlinear camera model...
  100. doi Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas
    Sean A Grimm
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Neurooncol 110:237-43. 2012
    ..2 mg/kg; (2) TMZ 75 mg/m(2)/ATO 0.2 mg/kg; (3) TMZ 75 mg/m(2)/ATO 0.25 mg/kg. Dose-limiting toxicity (DLT) was defined as grade 3 non-hematologic toxicity or grade 4 toxicity of any type from enrollment until 3 weeks ..
  101. doi Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I
    Sylvain Fouliard
    Institut de Recherches Internationales Servier, Clinical Pharmacokinetics, Suresnes, France
    Eur J Cancer 49:2791-7. 2013
    ..The dose limiting toxicity (DLT), consistently observed across all these schedules, was reversible thrombocytopenia...

Research Grants62

  1. Fatty Acid Synthase Inhibitors: Ovarian Cancer Therapy
    ALBERT OWENS; Fiscal Year: 2007
    ..cell line OVCAR-3; 3) a determination of the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) in BALB/C mice on low and high fat diets; and, 4) efficacy studies using OVCAR-3 xenografts grown in athymic BALB/..
  2. Correlative Studies for NCI Study#7916: Phase I Clinical Trial of Intravenous FAU
    Patricia Mucci LoRusso; Fiscal Year: 2010
    ..when administered as a 1-hour infusion on days 1-5 of a 28-day cycle, to determine the dose limiting toxicities (DLT), and to establish the maximum tolerated dose (MTD)...
  3. Phase 1 of AR-42 in relapsed CLL, lymphoma, myeloma
    Craig C Hofmeister; Fiscal Year: 2012
    ..AR-42 Mon/Wed/Fri in cycles of 28 days (three weeks on, one week off) to determine dose limiting toxicity (DLT), maximum tolerated dose (MTD), and toxicity profile of AR-42;2a) To examine circulating CLL cells from patients ..
  4. Hsp90 as a Target for the Treatment of Childhood Cancer
    Rochelle Bagatell; Fiscal Year: 2010
    ..Primary objectives of the trial will be to establish the Dose Limiting Toxicity (DLT) and the Maximum Tolerated Dose (MTD) of 17-DMAG in these patients and to assess the extent to which the MTD of ..
  5. A Novel Therapy for the Treatment of Chest Wall Progression of Breast Cancer
    Gary S Rogers; Fiscal Year: 2010
    ..a first-generation prototype CLIPT System that is presently being used in a Phase I, dose-limiting toxicity (DLT) human clinical trial with highly promising results...
  6. Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients with High-
    Nai Kong V Cheung; Fiscal Year: 2012
    ..the maximum tolerated dose (MTD) with minimal/no pain side effects, and MTD with no dose-limiting toxicity (DLT). The secondary goal is to study the pharmacokinetics (PK) of hu3F8. The last goal is to assess anti-tumor activity...
  7. Enteric-Coated Oral Beclomethasone Dipropionate in Patients with Acute Enteritis
    CHRISTOPHER JOSEPH SCHABER; Fiscal Year: 2010
    ..4-weeks post-RT, or until the patient is withdrawn earlier from the study, and will be reviewed for assessment of DLT. The safety results will be reviewed by the Principal Investigator(s) (PIs) and the DOR Medical Monitor...
  8. Modulating the tumor micro-environment in CLL using flavopiridol and lenalidomide
    Kristie Blum; Fiscal Year: 2009
    ..escalation trial of flavopiridol and lenalidomide to determine the specific toxicities, dose limiting toxicity (DLT), maximum tolerated dose (MTD), and preliminary efficacy of this combination in patients with previously treated B-..
  9. COMBINED RADIOIMMUNOTHERAPY & CHEMOTHERAPY--COLON CANCER
    Malik Juweid; Fiscal Year: 1999
    ..The dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of combined RAIT and 5-FU-LV has therefore, to be established experimentally, ..
  10. A Phase I Study of Single Agent Flavopiridol in B-Cell *
    Thomas Lin; Fiscal Year: 2007
    ..using this dosing schedule in patients with relapsed B-NHL, in order to determine the dose limiting toxicity (DLT), maximum tolerated dose (MTD) and toxicity profile of this dosing schedule in 1) indolent B-NHL, 2) MCL, and 3) ..
  11. MAX DALE COOPER; Fiscal Year: 2016
    ..Recent studies indicate that VLRA assembly and expression coincides with expression of cytidine deaminase 1 (CDA1) only within the lymphoepithelial thymoid gill region, whereas VLRB and CDA2 expression occurs primarily in ..
  12. MAX DALE COOPER; Fiscal Year: 2016
    ..Recent studies indicate that while VLRA gene assembly coincides with expression of cytidine deaminase 1 (CDA1) within the lymphoepithelial thymoid gill region, coincident VLRB and CDA2 expression instead occurs primarily in ..
  13. LINETTE BOSQUES; Fiscal Year: 2015
    ..This project will help us elucidate the role that codanin plays in control o erythropoiesis and megakaryopoiesis in attempts to better understand the mechanisms of bone marrow failure disorders. ..
  14. Stephan R Targan; Fiscal Year: 2015
    ..CD patients treated with anti-IFN-y MAb showed marked clinical improvement (decreased CDAI) and reduction in CRP...
  15. Jennifer L Collinger; Fiscal Year: 2014
    ..first author publications are expected to result from this work and the nominee will submit a CDA2 proposal as the CDA1 nears completion...
  16. Steven A Yukl; Fiscal Year: 2015
    ..The knowledge thus gained may ultimately contribute to new and improved therapies aimed at eradication or lifelong coexistence with HIV. ..
  17. Quantification of HIV-1 Reservoirs in the Gut
    Steven Yukl; Fiscal Year: 2010
    ....
  18. Impact of Cognitive Reserve on Memory Functioning in Multiple Sclerosis
    JAMES FRANCIS SUMOWSKI; Fiscal Year: 2012
    ..Finally, as a tertiary aim, I will perform the first investigation ofthe neuroanatomical basis of CR in persons with MS. ..
  19. Statistical Methods and Issues for Implementing Adaptive Phase I Trials
    Daniel P Normolle; Fiscal Year: 2013
    ..Aim 5 proposes methods for inference about the DLT rate for each dose after a Phase I trial has completed enrollment, information that is rarely considered once a ..
  20. Molecular Correlates--Oxaliplatin/5FU/XRT, Esophageal CA
    Lakshmi Pendyala; Fiscal Year: 2002
    ..between PK and changes in intratumoral gene expression and 4) maximum tolerated dose (MTD), dose limiting toxicity (DLT), and the potential therapeutic responses to OXP when given with continuous infusion 5FU + XRT...
  21. Immunotoxin-Induced Vascular Leak Syndrome
    Ellen Vitetta; Fiscal Year: 2005
    ..The response rate has been 40% and the dose limiting toxicity (DLT) has been vascular leak syndrome (VLS)...
  22. Phase ii intraperitoneal rhIL 12
    Ralph Freedman; Fiscal Year: 2002
    ..We have determined the dose limiting toxicity (DLT) of IP rhIL-12 (Genetics Institute) in a phase I clinical trial in a once weekly IP injection schedule...
  23. RAIT OF LUNG CANCER WITH RESIDUALIZING LABELS
    Rhona Stein; Fiscal Year: 2000
    ..we will begin by seeking to find an alternative conjugation chemistry which will retain the benefits of the DLT methodology used in our work thus far (i.e...
  24. ZINC SUPPLEMENTATION IN CROHN'S DISEASE PATIENTS
    Robert DiSilvestro; Fiscal Year: 2001
    ..Crohn's disease (N=15), beneficially impacts measurements of general zinc function, Crohn's disease activity index (CDAI), immune function and free radical-mediated oxidant stress...
  25. DEVELOPMENT OF POLY-L-GLUTAMIC ACID PACLITAXEL CONJUGATE
    Sidney Wallace; Fiscal Year: 2005
    ..This study will determine MTD, DLT, pharmacokinetics, assess toxicity, and document patient costs...
  26. Mark R Conaway; Fiscal Year: 2016
    ..follow a 'simple order' because the ordering of the probabilities of a 'dose-limiting toxicity'(DLT) for any pair of doses is known;administration of greater doses of the agent can be expected to produce DLT's ..
  27. A Phase I/II Clinical Trial of Intravenous (I.V.) Calcitriol with Fixed Doses of
    Nithya Ramnath; Fiscal Year: 2009
    ..phase I/II clinical study will be (1) to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of calcitriol in combination with cisplatin/docetaxel in patients with advanced NSCLC, (2) to assess the response ..
  28. Influence of the Host Cell Molecular Environment on Toxoplasma Development
    Jay Radke; Fiscal Year: 2009
    ..One host mRNA expressed in the Compound 1-altered cell, called cell division autoantigen 1 (CDA1), is able to induce parasite development when over-expressed in the infected host cell alone...
  29. A CLINICAL TRIAL OF THALIDOMIDE FOR CROHN'S DISEASE
    Eli Ehrenpreis; Fiscal Year: 2000
    ..Neither the patient or physician will be aware of the administered treatment. Crohn's Disease Activity Index (CDAI), a Physician Global Score, and blood work including CBC, erythrocyte sedimentation rate (ESR), C reactive protein (..
  30. Effects of naltrexone on active Crohn's disease
    Jill Smith; Fiscal Year: 2007
    ..with active Crohn's disease and found significant improvement in the Crohn's Disease Activity Index (CDAI) as well as endoscopic reversal of inflammation...
  31. NEUREXIN IV, GROWTH CONTROL, AND CANCER
    Manzoor Bhat; Fiscal Year: 2002
    ..Mutational analysis of the gene encoding this protein, discs lost (dlt), suggest that it may also play a role in the control of cell proliferation: in the absence of DLT protein, ..
  32. A Conceputal and Empirical Analysis of Cost Analysis
    Aaron Beaston Blaakman; Fiscal Year: 2005
    ..an empirical reliability study of a brief, telephone-based, cost analysis instrument (Cost Data Audit Instrument, CDAI) used in the Alcohol and Drug Services Study (ADSS)...
  33. A Novel Dosing Schedule of Flavopiridol in CLL
    Thomas Lin; Fiscal Year: 2006
    ..in relapsed CLL patients with p53 dysfunction, and acute tumor lysis has been observed as a dose limiting toxicity (DLT)...
  34. PRECLINICAL PHARMACOLOGY OF CANCER & AIDS DRUGS
    Nancy Turner; Fiscal Year: 1999
    ..For each drug, it will be necessary to establish a maximum tolerated dose (MTD) and dose limiting toxicities (DLT) in both beagle dogs and rodents...
  35. Lapatinib in childhood CNS malignancies
    Maryam Fouladi; Fiscal Year: 2006
    ..The primary aims of this proposal are a) to determine the maximum tolerated dose (MTD), dose limiting toxicities (DLT) and pharmacokinetics (PK) of Lapatinib in children with recurrent CNS malignancies in a phase I study; b) to ..
  36. ORGANIZATION OF APICAL CELL JUNCTIONS IN EYE
    Kwang Wook Choi; Fiscal Year: 2005
    ..domain (Crb intra) can recruit a MAGUK family protein Stardust (Sdt) and a PDZ domain protein Discs-lost (Dlt) to form a protein complex...
  37. Phase II Study of 44Gy from 131I-81C6 for CNS Tumors
    David Reardon; Fiscal Year: 2004
    ..To further define the toxicity of this approach and Specific Aim 3.To determine the impact of this therapy on quality of life. ..
  38. IMMUNOMODULATION IN INFLAMMATORY BOWEL DISEASE
    BRUCE SANDS; Fiscal Year: 2004
    ..The principal investigator seeks to become an independent clinical investigator by completing the didactic and scientific portions of this proposal. ..
  39. IMURAN Dose Ranging Study in Crohn's Disease
    BRUCE SANDS; Fiscal Year: 2005
    ..Abstract Not Provided ..
  40. CLINICAL TRIALS OF FLAVOPIRIDOL WITH CHEMOTHERAPY
    Gary Schwartz; Fiscal Year: 2008
    ..Continue to examine the mechanisms by which flavopiridol potentiates CPT-11 induced apoptosis, which should provide the opportunity to identify new biomarkers of response for these flavopiridol drug combinations. ..
  41. Multi-site Trial of Azathioprine Dosing in Crohn Disease
    Stephen Hanauer; Fiscal Year: 2004
    ..Predictive models will be performed to assess responsiveness based upon initial and inducible TPMT activity and achievable 6-TGN and 6-MMPR metabolite based upon incremental AZA dosing. ..
  42. OSCCAR: A Novel, Population-based Prospective Inception Cohort of Inflammatory Bo
    BRUCE SANDS; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  43. An Exploratory Study of UCN-01 and Irinotecan in Advanced Triple Negative Breast
    Paula Fracasso; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  44. Phase I Trial of Safingol and Cisplatin
    Gary Schwartz; Fiscal Year: 2006
    ..conduct "proof of principle" biological assays to measure the degree of ceramide production and/or S1P inhibition, either of which may be predictive of clinical outcome or toxicity. ..
  45. MENTORING FOR NEW CANCER THERAPEAUTICS
    Gary Schwartz; Fiscal Year: 2005
    ..This K24 award mechanism represents the essence of what we are proposing and for which support is needed. ..
  46. Multi-site Trial of Azathioprine Dosing in Crohn Disease
    Stephen Hanauer; Fiscal Year: 2003
    ..Predictive models will be performed to assess responsiveness based upon initial and inducible TPMT activity and achievable 6-TGN and 6-MMPR metabolite based upon incremental AZA dosing. ..
  47. PEDIATRIC BRAIN TUMOR RESEARCH CENTER
    Susan Blaney; Fiscal Year: 2003
    ..It offers leadership in the development of new agents, in new uses of sophisticated radiotherapy, and in the application of new approaches to brain tumor therapy. ..
  48. Phase II Study of Imatinib Mesylate in Patients with Inoperable Melanoma
    Gary K Schwartz; Fiscal Year: 2010
    ..Dose reductions are allowed in the setting of toxicity. Imaging studies will be performed on an every 6 week schedule. ..
  49. NABTT-Consortium Therapeutic Studies of CNS Malignancies
    Stuart Grossman; Fiscal Year: 2008
    ..abstract_text> ..
  50. Biochemical markers of bone turnover in metastatic prostate cancer
    Primo N Lara; Fiscal Year: 2010
    ....
  51. STUDY OF REG RECEPTOR-LIGAND BIOLOGY IN GI MUCOSA
    Brian Dieckgraefe; Fiscal Year: 2008
    ..These studies will also provide new insight into the role of Reg IV antagonists and lay the groundwork for development of therapeutic reagents active in gastrointestinal adenocarcinomas. ..
  52. Molecular Characterization of p53R2 in Head and Neck Ca
    Stuart Wong; Fiscal Year: 2004
    ..We will identify and characterize the frequency of p53R2 gene SNPs in HNSCC patients and test the hypothesis that p53R2 gene SNPs predict adverse normal tissue radiation effects in HNSCC patients treated with radiation. ..
  53. Pirfenidone in Children with PNs in NF1
    Roger Packer; Fiscal Year: 2006
    ..Abstract Not Provided ..
  54. A Novel Vitamin D Target in Human Prostate Cancer
    TOMASZ BEER; Fiscal Year: 2007
    ..New treatment targets are needed to develop new drugs to treat prostate cancer, the most commonly diagnosed cancer and the second-leading cancer killer in US men. [unreadable] [unreadable]..
  55. CHILDHOOD VACCINES AND DENTAL CARIES IMMUNITY
    Daniel Smith; Fiscal Year: 2007
    ..unreadable]..
  56. Phase I Clinical Trials of Anti-Cancer Agents
    Francis Giles; Fiscal Year: 2007
    ..abstract_text> ..
  57. Rapamycin as an Antineoplastic Agent
    Ezra Cohen; Fiscal Year: 2006
    ..At the conclusion of the trial RAPA toxicity and effect on p-S6K will be defined over a range of doses as well as the MTD for use in future studies that will develop this agent. ..
  58. Dendritic Cell Immunotherapy of Malignant Gliomas
    John Sampson; Fiscal Year: 2006
    ..abstract_text> ..
  59. DFMO Prevention Study (2b) in Organ Transplant Subjects
    Howard Bailey; Fiscal Year: 2005
    ..abstract_text> ..
  60. Chemoprevention of Skin Cancer - DFMO Phase III Trial
    Howard Bailey; Fiscal Year: 2005
    ..Ototoxicity and gastrointestinal toxicity have been most common). The objectives, which are unchanged from our original proposal, are all on schedule to be completed in the next 1-2 years. ..
  61. Cancer in the Middle Eastern Population in California
    Kiumarss Nasseri; Fiscal Year: 2004
    ..Patterns in the Middle Eastern population and will be compared to patterns in other racial and ethnic groups in California. ..